Resmetirom: Indications, Pharmacology, Warnings, and Precautions

Overview:

Resmetirom is an inventive therapeutic choice that is endorsed for a specific liver condition: noncirrhotic, nonalcoholic steatohepatitis. Resmetirom was conferred with the United States Food and Drug Administration’s licensure on March 14, 2024. Resmetirom, thus, acquires the title of the first drug therapy for noncirrhotic nonalcoholic steatohepatitis in the presence of conspicuous liver scarring and has secured authorization and license for its therapeutic implementation in noncirrhotic nonalcoholic steatohepatitis patients.

Until then, there were no drugs that could address noncirrhotic, nonalcoholic steatohepatitis in the presence of conspicuous liver scarring. The FDA (Food and Drug Administration) granted Resmetirom licensure through an accelerated approval scheme owing to its therapeutic merit within 12 months of a long-term (54-month) study. Considering the emergency of Resmetirom’s licensure to counter an unserved medical obligation, it was headed through a priority review and fast-track channel to make it accessible for the appropriate cases.

Drug Group:

Thyroid hormone receptor-beta agonist is the drug group for which Resmetirom is designated. Therefore, Resmetirom’s functions concern the thyroid hormone’s beta receptors, sparing the alpha receptors. This restricts and delimits Resmetirom’s activities within the liver, where beta receptors are primarily expressed.

Available Doses and Dosage Forms:

• Available Doses: 60 milligrams (mg), 80, and 100 mg are available.

• Dosage Forms: Tablet form.

• Route of Intake: To be ingested orally.

For Patients:

What Is Noncirrhotic Nonalcoholic Steatohepatitis?

Noncirrhotic nonalcoholic steatohepatitis, otherwise designated as NASH, is a peculiar liver condition that emerges in nonalcoholic individuals in which fat molecules congregate and amass in the liver cells. Upon getting into the liver cells, these fat molecules inflict liver cell harm, eventually invoking liver inflammation (swollen liver triggering abdominal pain and discomfort). Liver inflammation, over time, advances such that liver cells get mutilated, impairing their functionalities. Following this, the liver cells bring out scarring (disfigurement and roughening). Nonalcoholic fatty liver disease is the umbrella term that encompasses all the nonalcoholic forms of liver ailments, like noncirrhotic nonalcoholic steatohepatitis. Upper belly pain, an unreasonable drop in body weight, exhaustion, pruritus (itchy skin), a tendency to bleed, jaundiced skin, and tiredness are the manifestations inflicted by noncirrhotic, nonalcoholic steatohepatitis.

No studies could expose and unveil the real culprits behind noncirrhotic, nonalcoholic steatohepatitis. Unlike other liver conditions, it is not instigated by alcohol consumption, as elucidated by its incidence in nonalcoholic ones. Some risk quotients like overweight (obesity), inflated blood cholesterol (hyperlipidemia) and sugar (hyperglycemia) proportion, mitigated thyroid and pituitary functions, and hypertension (overstated blood pressure) are known to heighten one’s gravity for noncirrhotic nonalcoholic steatohepatitis.

How Does Resmetirom Work?

Resmetirom, a thyroid hormone receptor-beta agonist, exerts its effects by down-turning the lipid (fat) profile within the liver cells. Lipid congregation within the liver cells calls forth noncirrhotic nonalcoholic steatohepatitis. So, by mitigating lipid gathering, Resmetirom obviates liver cell mutilation. Resmetirom favors and encourages the pathway that eats up the fat molecules, thus depleting the liver cells’ fat proportion.

What Is the Dosage of Resmetirom?

Resmetirom’s dosage is devised in line with the individual’s body weight.

• Under 100-Kilogram Body Weight: 80-milligram Resmetirom daily.

• Over 100-Kilogram Body Weight: 100-milligram Resmetirom daily.

How Effective Is Resmetirom?

Resmetirom showcases exceptional therapeutic traits in noncirrhotic, nonalcoholic steatohepatitis patients. Resmetirom’s therapeutics, when weighed up against other thyroid hormone receptor beta agonists, expressed more command over the management of noncirrhotic, nonalcoholic steatohepatitis.

Other investigational thyroid hormone receptor beta agonists, despite downscaling the liver cells’ fat, bring forth evidence underscoring the propensity for undesirable downsides like unresponsiveness to insulin hormone, cartilage destruction, and hyperglycemia when instituted for longer periods. All these findings were derived through nonclinical trials, which forced the sponsor to break off those investigations. On the other hand, Resmetirom, upon investigational analysis, expressed superlative attributes with the slightest inclination for adversity.

In addition, Resmetirom, a thyroid hormone receptor beta agonist, withholds and slows down its actions within the liver while excusing the alpha receptors expressed in other vital organs. This stamps out the scope for unwanted effects prompted by Resmetirom on alpha receptors.

What Are the Things to Inform the Doctor Before Taking the Drug?

• Resmetirom Allergy: Overstated or unusual reactivity expressed with Resmetirom.

• Drug Allergy: Allergic response exhibited with other medications.

• Medical Background: Illness and ailments suffered, operations underwent, and other medical interventions sought.

• Present Health Status: Present health profile, including current ailments, disabilities, and mental state.

• Drug History: All the medicines, prescription and off-label medicines.

• Dietary Supplements: Herbal and nutritional supplementary therapies are undergoing.

• Pregnancy: Stage of pregnancy or intention for conception.

• Lactation: Nurse a baby during the Resmetirom course.

How Is Resmetrom Administered?

As retailed in tablet formulation, Resmetirom ought to be ingested orally. It is often gulped down with water unless the medical team insists otherwise. Resmetirom intake could either be accompanied by meals or delivered post-meal. Both ways are appropriate and advisable, as striking alterations were not made with food.

What Are the Side Effects of Resmetirom?

• Nausea (tendency to throw up).

• Diarrhea.

• Constipation.

• Stomach pain (upper portion).

• Vomiting.

• Tiredness.

• Skin rash.

• Fever.

• Yellow skin.

• Gallstones (solidified bile that could clog the bile track).

• Gallbladder inflammation (cholecystitis).

Dietary Considerations:

Resmetirom therapy does not call for distinct dietary revisions. However, at times, owing to the person’s health and medical status, certain revisions must be brought in to yield the best treatment pay-offs. Noncirrhotic nonalcoholic steatohepatitis mandates specific dietary revisions, to which one ought to adhere. Dietary changes affirmative of the noncirrhotic nonalcoholic steatohepatitis upscale Resmetirom’s effectiveness.

Missed Dose:

In case Resmetirom ingestion is missed, upon recollecting it, take the tablet if the upcoming dose is at bay. On the contrary, if one looks back on the missed Resmetirom dose quite late when the successive dose is close by, the passed-over Resmetirom ought to be disregarded while the successive dose could be ingested promptly. No doubling of the Resmetirom dose should be instituted to offset the overlooked Resmetirom dose. Doing so could bring in overdosing issues and may foster complications.

Overdose:

Being an investigational drug that is still in its trial phase, Resmetirom’s overdose attributes are yet to be unmasked and worked out. Not much data is revealed or made accessible. Having said that, if one takes up Resmetirom in doses that overstep the prescribed quantity, come in for medical assistance at the earliest moment.

Storage:

• Packaging: Marketed in miniature-sized medicine bottles.

• Ideal Storage Temperature: 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit).

• Permissible Storage Temperature: 15 to 30 degrees Celsius (59 to 86 degrees Fahrenheit).

For Doctors:

Indication:

• Noncirrhotic nonalcoholic steatohepatitis (complicated with obvious liver fibrosis of grades F2 and F3).

Dose:

An individual’s body weight is the decisive variable and criterion concerning Resmetirom’s dosage:

• Daily Dosage of Resmetirom for Body Weight Under 100 Kilograms: 80 milligrams.

• Daily Dosage of Resmetirom for Body Weight Exceeding 100 Kilograms: 100 milligrams.

Dosing Considerations:

Dosing considerations are being instituted for Resmetirom when Resmetirom has to be teamed with Clopidogrel. In such cases, the following dose revision ought to be instituted:

• Daily Dosage of Resmetirom for Body Weight Under 100 Kilograms: 60 milligrams.

• Daily Dosage of Resmetirom for Body Weight Exceeding 100 Kilograms: 80 milligrams.

One with decompensated cirrhosis should be held back from Resmetirom therapy owing to the propensity for grave outcomes. Severely threatened renal functions also call for dosing revisions or even abstinence from Resmetirom therapy.

What Are the Pharmacological Aspects of Resmetirom?

• Mechanism of Action: Thyroid hormone receptor-beta agonism is the core concept based on which Resmetirom tackles noncirrhotic, nonalcoholic steatohepatitis. Resmetirom drug molecule, a thyroid hormone receptor-beta agonist, connects with the thyroid hormone receptor, particularly beta receptors. These receptors are mapped within the hepatocytes. The interaction between the thyroid hormone receptor-beta and Resmetirom instigates conformational adjustments in the receptor entities. The complex constituted by the receptor assemblage with the Resmetirom tether with the thyroid hormone response element (TREs) yields altered and unfavorable gene expressions. Thus, invoked oddities in the genetic expression inflicted by Resmetirom underscore the lipid metabolism. It tackles steatohepatitis by mitigating lipid proportion within the liver cells by heightening lipid breakdown and down-trending lipogenesis. Resmetirom also downscales the fibrogenesis process, thus palliating liver fibrosis.

• Pharmacodynamics: Resmetirom also deflates the FT4 (free thyroxine) proportion. At the same time, It upturns the sex hormone binding protein (SHBP) proportion throughout the therapy courses. Hepatocytes’ fat content also shows a striking and pronounced diminution, which expedites Resmetirom’s therapeutics in noncirrhotic, nonalcoholic steatohepatitis.

• Pharmacokinetics: After commencing Resmetirom therapy, one secures a constant Resmetirom concentration in the blood in three to six days, provided the medicament is being instituted daily. Four hours post-Resmetirom ingestion, its concentration reaches its peak value. Resmetirom’s peak value expresses a downfall of 33 percent when food intake is instituted alongside drug delivery. Resmetirom is dispensed by complexing with plasma proteins. Cytochrome P2C8 (CYP2C8) knocks down the Resmetirom-yielding metabolites. Resmetirom’s prime elimination pathway is fecal (around 67 percent); nevertheless, the urinary pathway also gives off a smaller (around 24 percent) drug quota.

Toxicity:

• Overdose Toxicity: No Resmetirom overdosing reports have been documented, and hence, toxicity manifestations are yet to be looked into.

• Carcinogenesis: Animal studies underscored and unfolded Resmetirom’s capability to inflict carcinogenesis. However, higher dosages only invoked carcinogenesis incidences, while no apparent carcinogenesis was fostered in the lower doses.

• Mutagenesis: Chromosomal aberration test and Ames test derived negative results.

Clinical Studies:

Resmetirom’s therapeutics were comprehended through a randomized, placebo-controlled, and double-blinded study. The actual study duration is 54 months, but once it covered 12 months, owing to the immediate need for the drug, its safety and efficacy attributes were scrutinized. The study is still making headway in exploring more aspects of Resmetirom, revealing its whole clinical attributes and long-term upshots. Noncirrhotic nonalcoholic steatohepatitis, marked with liver scarring of grades 2 or 3, was designated for the trial. Both 100-milligram and 80-milligram doses were trialed in discrete subject batches, and both batches revealed and underscored palliation of steatohepatitis. Certain patients even expressed downregulation in the liver fibrosis grading, which is a much more appreciable attribute. These results were obtained through histopathological scrutiny.

What Are the Contraindications of Resmetirom?

• Resmetirom allergy.

Warnings and Precautions:

• Gallbladder Problems: Resmetirom might exaggerate the propensity for certain gallbladder issues. Acute cholecystitis and gallstone occurrences were delineated and documented in Resmetirom-treated patients, expressing an overstated proneness to gallbladder issues. Gallstones, at times, bring forth obstructive pancreatitis by clogging up and sealing off the bile duct. Upon precipitation of gallbladder issues like cholelithiasis, break off Resmetirom therapy until the severity has been reduced.

• Hepatotoxicity: Resmetirom could bring forth hepatotoxicity issues. Biochemical attributes of the liver through alanine aminotransferase, total bilirubin, and aspartate aminotransferase expressed unreasonable inflation all through Resmetirom therapy. However, this upscaling clears up once Resmetirom is withdrawn. Therefore, liver biochemistry should be tracked throughout Resmetirom therapy to address hepatotoxicity issues much earlier. The patient also must be familiarized with the hepatotoxicity manifestations that Resmetirom brings out. Appreciation upscaling in liver enzymes calls for the suspension of Resmetirom therapy.

What Are the Drug Interactions of Resmetirom?

• Interaction With Cytochrome P2C8 (CYP2C8): Moderate or strong CYP2C8 upscales Resmetirom’s concentration, encouraging the gravity of side effects.

• Interaction With Organic Anion Transporting Polypeptides: It could markedly upregulate Resmetirom's concentration hence, concomitant advocating is undesired.

• Interaction With Statins: Resmetirom inflames and inflates statin concentration, which calls for downregulating statin dose.

Specific Considerations:

• Resmetirom During Pregnancy: Being an investigational medicament, Resmetirom’s safety facets have not been looked into, particularly in expectant women. Therefore, the gravity of Resmetirom for inflicting birth defects or fetal harm is obscure and undisclosed. This holds down the therapeutic employment of Resmetirom in expectant women.

• Resmetirom During Breastfeeding: Resmetirom has not yet been researched and tested in lactating women. Therefore, whether It passes through breast milk or not is still a mystery.

• Resmetirom in Pediatric Patients: Resmetirom’s therapeutic traits in younger patients have yet to be validated, thus delimiting its relevance and application in pediatrics.

• Resmetirom in Geriatric Patients: Geriatric patients do not cause any downfall in Resmetirom’s therapeutic traits. However, Resmetirom expresses an overstated gravity of adverse reactions in elderly patients.